2cureX launches IndiTreat.com as an important component of 2cureX’s preparation for the product launch of IndiTreat® in 2020

IndiTreat.com is dedicated to colorectal cancer being the first cancer entity where the IndiTreat® test will be marketed. 2cureX is conducting clinical validation in other cancers like ovarian and pancreatic cancer – these cancers will be added to the IndiTreat.com site when clinical support is released from the company’s ongoing clinical studies. The IndiTreat.com website will help both patients/relatives and healthcare professionals in understanding the IndiTreat® test, identify which patients are eligible and how these patients can be provided the IndiTreat® test.

The European patient organisation Digestive Cancers Europe (DiCE) advocates for the use of state-of-the-art cancer diagnosis and treatment for all European patients with digestive cancers”, states Stefan Gijssels, Executive Director DICE “We therefore support the development and roll-out of a functional test. Immediate identification of an effective treatment is key to the overall treatment success. Patients should be informed about the technology so that they can co-decide about its use”.

Ole Thastrup, Chief Executive Officer, 2cureX says: “Development and patent protection of the IndiTreat® test has been a long and challenging process; but its acceptance by prominent clinical institutions and among patients has been surprisingly fast. It is therefore a pleasure for me to support and guide the many patients, patient societies and doctors that contact us, by launching the Inditreat.com website”.

www.IndiTreat.com is fully accessible as of now as a unique URL or can be visited through www.2cureX.com

For more information about 2cureX:

Ole Thastrup, CEO
E-mail: ot@2cureX.com
Phone: +45 22 11 53 99
URL: www.2curex.com
 

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telephone: +46 70 755 95 51
E-mail: ca@skmg.se

About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment Design) test. IndiTreat establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour and identifies the approved cancer treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient will be provided the selected treatment.

IndiTreat is being clinically validated in eight clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and the United Kingdom.

IndiTreat is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat is presently being introduced into the European market through an Early Access Program.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).